Zenyatta Ventures Ltd Share Price Toronto S.E.
Equities
CA98943A1012
Biotechnology & Medical Research
Sales 2022 | 0.35 0.47 27.37 | Sales 2023 | 0.07 0.1 5.74 | Capitalization | 206M 280M 16.24B |
---|---|---|---|---|---|
Net income 2022 | -38M -51.72M -3B | Net income 2023 | -14M -19.05M -1.1B | EV / Sales 2022 | 1,031,593,065 x |
Net cash position 2022 | 24.44M 33.27M 1.93B | Net cash position 2023 | 8.75M 11.9M 689M | EV / Sales 2023 | 2,707,984,696 x |
P/E ratio 2022 |
-9.19
x | P/E ratio 2023 |
-14.3
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 94.07% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Fenton
CEO | Chief Executive Officer | - | 10/07/18 |
Wendy Ford
DFI | Director of Finance/CFO | - | 15/05/22 |
Adam MacIntosh
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ilse Treurnicht
BRD | Director/Board Member | - | 04/07/22 |
John Snisarenko
BRD | Director/Board Member | 61 | 04/10/23 |
Francis Dubé
BRD | Director/Board Member | - | 10/05/18 |
1st Jan change | Capi. | |
---|---|---|
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |